Randall Schreck

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Dirk B. Mendel, Alexander Laird, Xiaohua Xin et al. · PubMed · 2003 · 2K citations

Tumor Xenografts, Mouse Xenograft Models, Active Dose +18

SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

T. Annie T. Fong, Laura K. Shawver, Li Sun et al. · PubMed · 1999 · 1K citations

Novel Synthetic Compound, Chemoprevention Strategy, Pathology +20

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

James G. Christensen, Randall Schreck, Jon Burrows et al. · PubMed · 2003 · 497 citations

Cancer Biology, Tumor Biology, C-met Kinase +20

Flk-1 as a target for tumor growth inhibition.

L M Strawn, Gerald McMahon, Harald App et al. · PubMed · 1996 · 318 citations

Endothelial Cells, Cancer Biology, Tumor Biology +18

Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases

Li Sun, Ngoc Quang Tran, Congxin Liang et al. · Journal of Medicinal Chemistry · 1999 · 271 citations · Full text

Tyrosine Kinase, Immunology, Pharmacotherapy +16